Saima Hassan

Montreal, QC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Precision targeting of the SASP in cancer therapy.

Precision targeting of the SASP in cancer therapy.

Journal: Nature aging

Published: February 03, 2026

2025 Canadian Surgery Forum: Sept. 17-20, 2025.

2025 Canadian Surgery Forum: Sept. 17-20, 2025.

Journal: Canadian journal of surgery. Journal canadien de chirurgie

Published: December 09, 2025

Treatment Patterns and Clinical Outcomes in Metastatic HR+/HER2- and Triple-Negative Breast Cancer in Canada: The HER2- TRENDS Study.

Treatment Patterns and Clinical Outcomes in Metastatic HR+/HER2- and Triple-Negative Breast Cancer in Canada: The HER2- TRENDS Study.

Journal: Advances in therapy

Published: December 05, 2025

Sequencing PARP inhibitors in breast cancer: lessons learned and emerging insights.

Sequencing PARP inhibitors in breast cancer: lessons learned and emerging insights.

Journal: NPJ breast cancer

Published: November 30, 2025

Estrogen-mediated NF-κB blockade enables breast cancer sensitivity to oncolytic VSV virotherapy.

Estrogen-mediated NF-κB blockade enables breast cancer sensitivity to oncolytic VSV virotherapy.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: November 10, 2025

Estrogen-mediated NF-κB blockade enables breast cancer sensitivity to oncolytic VSV virotherapy.

Estrogen-mediated NF-κB blockade enables breast cancer sensitivity to oncolytic VSV virotherapy.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: November 10, 2025

Evaluation of Recurrence Rate in Canadian Patients With Stage II/III HR+/HER2- Early Breast Cancer in the Real-World Setting.

Evaluation of Recurrence Rate in Canadian Patients With Stage II/III HR+/HER2- Early Breast Cancer in the Real-World Setting.

Journal: Breast cancer : basic and clinical research

Published: March 21, 2025

Targeting FEN1/EXO1 to enhance efficacy of PARP inhibition in triple-negative breast cancer.

Targeting FEN1/EXO1 to enhance efficacy of PARP inhibition in triple-negative breast cancer.

Journal: Translational oncology

Published: October 05, 2024

Leveraging PARP-1/2 to Target Distant Metastasis.

Leveraging PARP-1/2 to Target Distant Metastasis.

Journal: International journal of molecular sciences

Published: July 22, 2024

Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41.

Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41.

Journal: Breast cancer research and treatment

Published: November 30, 2022

Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer.

Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer.

Journal: British journal of cancer

Published: May 16, 2022

Impact of the 21-Gene Recurrence Score Assay on Treatment Decisions and Cost in Patients with Node-Positive Breast Cancer: A Multicenter Study in Quebec.

Impact of the 21-Gene Recurrence Score Assay on Treatment Decisions and Cost in Patients with Node-Positive Breast Cancer: A Multicenter Study in Quebec.

Journal: The oncologist

Published: January 14, 2022

Showing 1-12 of 21

Last Updated: 09/26/2026